PEPT

25.8251.96%

Eli Lilly hits record high in premarket

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Eli Lilly (LLY.US) rose more than 1% in premarket trading to a record high of $1,458.30.

The stock is up 7.84% over the past five sessions and up 36.52% year to date. It sits 72.21% above its 52-week low of US$846.80.

The Nasdaq Composite is up 2.27% over the past five sessions and up 8.15% year to date.

At the ObesityWeek 2026 conference, the company reported that its phase 2 candidate EloraTZP achieved average weight loss of 23.3%, or about 54.1 pounds, in adults with overweight or obesity and type 2 diabetes, while significantly improving hemoglobin A1c levels. Phase 3 data showed retatrutide reduced the severity of obstructive sleep apnea and knee osteoarthritis pain, and Zepbound lowered BMI by 21.4% in adolescents.

Separately, China's National Medical Products Administration approved Eli Lilly's oral GLP-1 weight-loss drug orforglipron calcium tablets on Nov. 12 for long-term weight management in adults, marking the first oral GLP-1 therapy cleared in the country. The company has also broken ground on a $3.5 billion advanced manufacturing facility in Pennsylvania focused on next-generation injectable obesity treatments, with operations expected to begin in 2031.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.